The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
It is tempting to celebrate big milestones. Novartis chief Vas Narasimhan can be forgiven for doing so. His focus is on higher-margin, innovative drugs. The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October.